Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans.
The relative bioavailability of sarpicillin (the methoxymethyl ester of hetacillin) from three different oral dosage forms was compared in humans employing a three-way crossover study design. Each unit dose contained 250 mg of sarpicillin in terms of anhydrous ampicillin activity. The comparative bioavailability of a tablet containing added buffer, a liquid-filled capsule, and a standard powder-filled capsule was determined. The bioavailability parameters were Cmax, tmax, and AUC of intact plasma sarpicillin levels and saliva ampicillin levels. Significant correlation was found between plasma sarpicillin levels and saliva ampicillin levels following the administration of sarpicillin. All three formulations yielded statistically similar Cmax and AUC values with respect to plasma sarpicillin and saliva ampicillin levels. However, a more rapid absorption of intact sarpicillin was observed with the buffered tablet formulation, as reflected by significantly smaller tmax for both plasma sarpicillin and saliva ampicillin levels. The faster absorption from the tablet formulation gave more precise absorption among subjects.
D000328:Adult; D000667:Ampicillin / Q000097:blood / Q000652:urine; D001682:Biological Availability; D002214:Capsules; D006801:Humans; D007700:Kinetics; D008297:Male; D010406:Penicillins / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000378:metabolism; D012463:Saliva / Q000378:metabolism; D013607:Tablets
D002214:Capsules; D010406:Penicillins; D013607:Tablets; D000667:Ampicillin; C014912:sarpicillin; C100115:hetacillin